- Home
- PRGO vs RNA Comparison
PRGO vs RNA Comparison
Compare PRGO & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGO | RNA |
|---|---|---|
| Founded | 1887 | 2012 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PRGO | RNA |
|---|---|---|
| Price | $10.78 | $14.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 20 |
| Target Price | $19.33 | ★ $69.26 |
| AVG Volume (30 Days) | 2.8M | ★ 2.9M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | $0.02 | $88.12 |
| Revenue Next Year | $1.36 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.13 | $13.06 |
| 52 Week High | $29.08 | $73.06 |
Technical Indicators
Market Signals| Indicator | PRGO | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 22.11 | 4.22 |
| Support Level | N/A | $13.06 |
| Resistance Level | $15.08 | $72.52 |
| Average True Range (ATR) | 0.60 | 0.83 |
| MACD | -0.41 | -6.15 |
| Stochastic Oscillator | 2.84 | 3.11 |
Price Performance
Historical ComparisonAbout PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. The company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.